Razafindrazoto C I, Rasolonjatovo A S, Randriamifidy N H, Rabarioely S S, Rakotozafindrabe A L R, Rabenjanahary T H, Razafimahefa S H, Ramanampamonjy R M
Unité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.
Unité de soins, de formation et de recherche, hépato-gastro-entérologie et de médecine interne, Fianarantsoa, Madagascar. Faculté de médecine de Fianarantsoa, Université de Fianarantsoa, Madagascar.
Med Trop Sante Int. 2021 Sep 16;1(3). doi: 10.48327/mtsibulletin.2021.153. eCollection 2021 Sep 30.
Our work aimed to assess the efficacy and safety of direct-acting antiviral drugs in the treatment of hepatitis C in Madagascar.
This retrospective clinical study was carried out from March 2018 to February 2020 in the hepato-gastro-enterology department of the University Hospital Center Joseph Raseta de Befelatanana.
A total of 35 patients were included, out of which 24 received sofosbuvir/ledipasvir ± ribavirin, 10 sofosbuvir/ribavirin and one sofosbuvir/velpatasvir. Thirty-three patients were naïve to the treatment and 2 patients were initially treated with the sofosbuvir/ledipasvir combination. The sustained virologic response was 94% (33/35) in the general population, 23/25 in cirrhotic patients and 10/10 in non-cirrhotic patients. The sustained virologic response was 22/24 for sofosbuvir/ledipasvir ± ribavirin, 10/10 for sofosbuvir/ribavirin and 1/1 for sofosbuvir/velpatasvir. Adverse effects were observed in 13 patients, mainly asthenia and insomnia.
The small number of patients with hepatitis C treatments and their limited financial resources are the main limits of this survey.
Direct-acting antivirals are effective and characterized by good tolerance in these Malagasy hepatitis C patients.
我们的工作旨在评估直接作用抗病毒药物治疗马达加斯加丙型肝炎的疗效和安全性。
这项回顾性临床研究于2018年3月至2020年2月在约瑟夫·拉塞塔·德贝费拉塔纳纳大学医院中心的胃肠肝病科进行。
共纳入35例患者，其中24例接受索磷布韦/维帕他韦±利巴韦林治疗，10例接受索磷布韦/利巴韦林治疗，1例接受索磷布韦/维帕他韦治疗。33例患者为初治患者，2例患者最初接受索磷布韦/维帕他韦联合治疗。总体人群的持续病毒学应答率为94%（33/35），肝硬化患者为23/25，非肝硬化患者为10/10。索磷布韦/维帕他韦±利巴韦林的持续病毒学应答率为22/24，索磷布韦/利巴韦林为10/10，索磷布韦/维帕他韦为1/1。13例患者出现不良反应，主要为乏力和失眠。
丙型肝炎治疗患者数量少以及资金有限是本次调查的主要局限。
直接作用抗病毒药物对这些马达加斯加丙型肝炎患者有效且耐受性良好。
